ZA200510170B - Method of reducing the harmful effects of orally or transdermally delivered nicotine - Google Patents

Method of reducing the harmful effects of orally or transdermally delivered nicotine

Info

Publication number
ZA200510170B
ZA200510170B ZA200510170A ZA200510170A ZA200510170B ZA 200510170 B ZA200510170 B ZA 200510170B ZA 200510170 A ZA200510170 A ZA 200510170A ZA 200510170 A ZA200510170 A ZA 200510170A ZA 200510170 B ZA200510170 B ZA 200510170B
Authority
ZA
South Africa
Prior art keywords
orally
reducing
harmful effects
transdermally delivered
delivered nicotine
Prior art date
Application number
ZA200510170A
Other languages
English (en)
Inventor
Conkling Mark
Original Assignee
Vector Tobacco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vector Tobacco Ltd filed Critical Vector Tobacco Ltd
Publication of ZA200510170B publication Critical patent/ZA200510170B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/20—Biochemical treatment
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/243—Nicotine
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/245—Nitrosamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
ZA200510170A 2003-06-04 2005-12-14 Method of reducing the harmful effects of orally or transdermally delivered nicotine ZA200510170B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47594503P 2003-06-04 2003-06-04

Publications (1)

Publication Number Publication Date
ZA200510170B true ZA200510170B (en) 2006-11-29

Family

ID=33551567

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200510170A ZA200510170B (en) 2003-06-04 2005-12-14 Method of reducing the harmful effects of orally or transdermally delivered nicotine

Country Status (10)

Country Link
US (1) US20060237025A1 (ja)
EP (1) EP1628681A4 (ja)
JP (1) JP2007528204A (ja)
KR (1) KR20060032141A (ja)
CN (1) CN1812811A (ja)
AR (1) AR044599A1 (ja)
AU (1) AU2004251635A1 (ja)
CA (1) CA2527648A1 (ja)
WO (1) WO2005000352A1 (ja)
ZA (1) ZA200510170B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1893043A4 (en) 2005-05-11 2013-07-31 Vector Tobacco Inc TOBACCO PRODUCTS WITH REDUCED RISKS AND PROCESS FOR PRODUCING THE SAME
CA2974319C (en) * 2007-06-01 2019-04-30 Syngenta Participations Ag Methods for the commercial production of transgenic plants
US7667106B2 (en) * 2007-11-06 2010-02-23 Alliance One International, Inc. Tobacco cultivar ‘AOB 175’
US7665472B2 (en) * 2007-11-06 2010-02-23 Alliance One International, Inc. Tobacco cultivar AOB 175 and products therefrom
AR075466A1 (es) 2008-10-22 2011-04-06 Basf Se Uso de herbicidas tipo auxina en plantas cultivadas
WO2010046423A2 (en) 2008-10-22 2010-04-29 Basf Se Use of sulfonylurea herbicides on cultivated plants
MX2015004175A (es) 2012-10-01 2015-06-10 Basf Se Uso de compuestos de n-tio-antranilamida en plantas cultivadas.
WO2014079820A1 (en) 2012-11-22 2014-05-30 Basf Se Use of anthranilamide compounds for reducing insect-vectored viral infections
CN103005703B (zh) * 2012-12-12 2015-04-15 广东中烟工业有限责任公司 一种基于烟气危害性指数的卷烟设计方法
CN103005702B (zh) * 2012-12-12 2015-03-18 广东中烟工业有限责任公司 一种深度抽吸下基于危害性指数的低危害卷烟设计方法
CN102940310B (zh) * 2012-12-12 2015-08-05 广东中烟工业有限责任公司 一种基于n-亚硝胺释放量的卷烟设计中各个组分的调整方法
EP3028573A1 (en) 2014-12-05 2016-06-08 Basf Se Use of a triazole fungicide on transgenic plants
WO2016091674A1 (en) 2014-12-12 2016-06-16 Basf Se Use of cyclaniliprole on cultivated plants
US11064696B2 (en) 2015-04-07 2021-07-20 Basf Agrochemical Products B.V. Use of an insecticidal carboxamide compound against pests on cultivated plants
EP3338552A1 (en) 2016-12-21 2018-06-27 Basf Se Use of a tetrazolinone fungicide on transgenic plants
WO2020003363A1 (ja) * 2018-06-25 2020-01-02 学校法人近畿大学 ニコチン摂取の影響による血管の劣化を防止するための健康食品または医薬組成物
EP4041899A1 (en) * 2019-10-10 2022-08-17 Altria Client Services LLC Compositions and methods based on qpt engineering for producing tobacco plants and products having altered alkaloid levels
CN113528537A (zh) * 2021-08-11 2021-10-22 云南省烟草农业科学研究院 一种降低烟叶烟碱含量的NtQPT2基因突变体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005646A1 (en) * 1991-09-13 1993-04-01 Technology Management Services, S.A. Reduction of nicotine levels in tobacco
WO2000067558A1 (en) * 1999-05-06 2000-11-16 Michael Timko Regulation of gene expression in tobacco for manipulation of plant growth and secondary metabolism
EP1292703B1 (en) * 2000-02-07 2007-04-25 Cristobal Guillermo Dos Remedios Biomolecular toxicity assay
CA2420724A1 (en) * 2000-08-30 2002-03-07 North Carolina State University Transgenic plants containing molecular decoys that alter protein content therein
AU2002228901A1 (en) * 2000-11-10 2002-05-21 Vector Tobacco (Bermuda) Ltd. Method and product for removing carcinogens from tobacco smoke
US20060157072A1 (en) * 2001-06-08 2006-07-20 Anthony Albino Method of reducing the harmful effects of orally or transdermally delivered nicotine
EP1406518A4 (en) * 2001-06-08 2006-03-29 Vector Tobacco Ltd CHANGES IN NICOTINE AND NITROSAMINE LEVELS IN TOBACCO
JP2005508648A (ja) * 2001-11-09 2005-04-07 ベクター・タバコ・インコーポレーテッド 炭でフィルターされた巻きタバコのメントール化のための組成物及び方法
EA200401332A1 (ru) * 2002-04-09 2005-02-24 Вектор Тобакко Лтд. Табак с пониженным содержанием никотина и нитрозаминов
US20050066986A1 (en) * 2003-09-30 2005-03-31 Nestor Timothy Brian Smokable rod for a cigarette

Also Published As

Publication number Publication date
KR20060032141A (ko) 2006-04-14
WO2005000352A1 (en) 2005-01-06
AU2004251635A1 (en) 2005-01-06
EP1628681A4 (en) 2009-07-15
EP1628681A1 (en) 2006-03-01
AR044599A1 (es) 2005-09-21
CN1812811A (zh) 2006-08-02
US20060237025A1 (en) 2006-10-26
CA2527648A1 (en) 2005-01-06
JP2007528204A (ja) 2007-10-11

Similar Documents

Publication Publication Date Title
ZA200510170B (en) Method of reducing the harmful effects of orally or transdermally delivered nicotine
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
EP1617805A4 (en) METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS
HK1103631A1 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
HUP0302739A3 (en) Method for the treatment of tobacco
AU2001285747A1 (en) Method for the treatment of tobacco
HK1083732A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
EP1551388A4 (en) COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, COMPOSITIONS AND METHODS COMPRISING THE SAME
HK1104800A1 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
GB0306309D0 (en) Method of treatment
GB0302572D0 (en) Method of treatment
EP1646640A4 (en) PROCESS FOR PREPARING HIGH-PURITY 1-ANDROSTEN DERIVATIVES
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB0221712D0 (en) Methods of treatment
AU2003209534A8 (en) The method of treating tuberculosis
IL172528A0 (en) Surface treatment of sars-infected lungs
GB0213198D0 (en) Method of treatment
AU2003293714A1 (en) Methods for the treatment of chronic pain and compositions therefor
GB0207091D0 (en) Method of treatment
AU2003902314A0 (en) Method of treatment of autonomic neuropathy
GB0208783D0 (en) Methods of treatment
GB0223254D0 (en) Methods of treatment
GB0311123D0 (en) Method of treatment
GB0312083D0 (en) Method of treatment